Blueprint Medicines (NASDAQ:BPMC) PT Raised to $80.00
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $80.00
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price objective increased by Morgan Stanley from $65.00 to $80.00 in a research note published on Friday, Marketbeat reports. Morgan Stanley currently has an equal weight rating on the biotechnology company's stock.
據Marketbeats報道,在週五發佈的一份研究報告中,藍圖醫藥(納斯達克:BPMC-GET評級)將摩根士丹利的目標價從65.00美元上調至80.00美元。摩根士丹利目前對這家生物技術公司的股票擁有同等權重的評級。
Other analysts have also recently issued research reports about the stock. Raymond James decreased their target price on shares of Blueprint Medicines from $133.00 to $115.00 and set a strong-buy rating on the stock in a research note on Wednesday, August 3rd. HC Wainwright decreased their target price on shares of Blueprint Medicines from $100.00 to $80.00 and set a buy rating on the stock in a research note on Wednesday, August 17th. The Goldman Sachs Group boosted their target price on shares of Blueprint Medicines from $126.00 to $143.00 and gave the stock a buy rating in a research note on Wednesday, August 3rd. Jefferies Financial Group boosted their target price on shares of Blueprint Medicines from $78.00 to $84.00 and gave the stock a buy rating in a research note on Monday, August 22nd. Finally, Stifel Nicolaus boosted their target price on shares of Blueprint Medicines from $93.00 to $100.00 and gave the stock a buy rating in a research note on Thursday, August 18th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $92.19.
其他分析師最近也發佈了關於該股的研究報告。8月3日,雷蒙德·詹姆斯在一份研究報告中將Blueprint Medicines的目標價從133.00美元下調至115.00美元,並對該股設定了強力買入評級。8月17日,HC Wainwright在一份研究報告中將Blueprint Medicines的目標價從100.00美元下調至80美元,並對該股設定了買入評級。高盛夫婦將藍圖醫藥的目標價從126.00美元上調至143.00美元,並在8月3日星期三的一份研究報告中給出了該股的買入評級。傑富瑞金融集團將Blueprint Medicines的目標價從78.00美元上調至84.00美元,並在8月22日(星期一)的一份研究報告中給予該股買入評級。最後,Stifel Nicolaus將Blueprint Medicines的目標價從93美元上調至100.00美元,並在8月18日星期四的一份研究報告中給出了該股的買入評級。兩名股票研究分析師對該股的評級為賣出,四名分析師給予持有評級,七名分析師給予買入評級,一名分析師對該股給予強烈買入評級。根據MarketBeat.com的數據,該公司目前的共識評級為適度買入,共識目標價為92.19美元。
Blueprint Medicines Price Performance
藍圖藥品價格表現
Shares of NASDAQ:BPMC opened at $75.47 on Friday. The company's 50 day simple moving average is $63.57 and its 200 day simple moving average is $60.69. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of -6.36 and a beta of 0.78. Blueprint Medicines has a 1 year low of $43.46 and a 1 year high of $117.86.
納斯達克:上週五開盤報75.47美元。該公司的50日簡單移動均線切入位在63.57美元,200日簡單移動均線切入位在60.69美元。該股市值為45億美元,市盈率為-6.36,貝塔係數為0.78。Blueprint Medicines的一年低點為43.46美元,一年高位為117.86美元。
Insider Activity at Blueprint Medicines
Blueprint Medicines的內部活動
In related news, insider Debra Durso-Bumpus sold 5,000 shares of the business's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $75.11, for a total value of $375,550.00. Following the transaction, the insider now owns 40,836 shares in the company, valued at $3,067,191.96. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, insider Debra Durso-Bumpus sold 5,000 shares of the business's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $75.11, for a total value of $375,550.00. Following the transaction, the insider now owns 40,836 shares in the company, valued at $3,067,191.96. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Christopher K. Murray sold 2,500 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $60.44, for a total transaction of $151,100.00. Following the completion of the transaction, the senior vice president now owns 21,320 shares in the company, valued at approximately $1,288,580.80. The disclosure for this sale can be found here. Insiders have sold a total of 47,500 shares of company stock worth $3,300,123 over the last quarter. Company insiders own 3.42% of the company's stock.
在相關新聞中,內部人士Debra Durso-Bumpus在8月24日星期三的一次交易中出售了5000股該公司的股票。這些股票的平均價格為75.11美元,總價值為375,550.00美元。交易完成後,這位內部人士現在擁有該公司40,836股,價值3,067,191.96美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個鏈接獲得。在相關新聞中,內部人士Debra Durso-Bumpus在8月24日星期三的一次交易中出售了5000股該公司的股票。這些股票的平均價格為75.11美元,總價值為375,550.00美元。交易完成後,這位內部人士現在擁有該公司40,836股,價值3,067,191.96美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個鏈接獲得。此外,高級副總裁克里斯托弗·K·默裏在8月4日(星期四)的一次交易中出售了2500股該公司的股票。這些股票的平均價格為60.44美元,總成交金額為151,100.00美元。交易完成後,高級副總裁現在擁有該公司21,320股,價值約1,288,580.80美元。此次拍賣的披露信息可在此處找到。在上個季度,內部人士總共出售了47,500股公司股票,價值3,300,123美元。公司內部人士持有該公司3.42%的股份。
Hedge Funds Weigh In On Blueprint Medicines
對衝基金看好Blueprint Medicines
Several institutional investors have recently made changes to their positions in BPMC. FMR LLC raised its holdings in shares of Blueprint Medicines by 60.8% during the second quarter. FMR LLC now owns 8,576,079 shares of the biotechnology company's stock valued at $433,178,000 after purchasing an additional 3,242,698 shares during the period. Cadian Capital Management LP raised its holdings in shares of Blueprint Medicines by 326.3% during the first quarter. Cadian Capital Management LP now owns 1,921,347 shares of the biotechnology company's stock valued at $122,736,000 after purchasing an additional 1,470,690 shares during the period. Marshall Wace LLP raised its holdings in shares of Blueprint Medicines by 3,407.4% during the fourth quarter. Marshall Wace LLP now owns 950,682 shares of the biotechnology company's stock valued at $101,827,000 after purchasing an additional 923,577 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Blueprint Medicines by 14.2% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,631,687 shares of the biotechnology company's stock worth $284,457,000 after acquiring an additional 698,562 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Blueprint Medicines during the second quarter worth about $34,599,000.
幾家機構投資者最近改變了他們在BPMC的頭寸。FMR LLC在第二季度將其在Blueprint Medicines的股票持有量增加了60.8%。FMR LLC現在擁有這家生物技術公司8,576,079股股票,價值433,178,000美元,在此期間又購買了3,242,698股。Cadian Capital Management LP在第一季度將其持有的Blueprint Medicines股票增加了326.3%。Cadian Capital Management LP現在擁有這家生物技術公司1,921,347股股票,價值122,736,000美元,在此期間又購買了1,470,690股。馬歇爾·華斯有限責任公司在第四季度將其持有的Blueprint Medicines股票增加了3,407.4%。馬歇爾·華斯有限責任公司在此期間又購買了923,577股,現在擁有950,682股這家生物技術公司的股票,價值101,827,000美元。Price T Rowe Associates Inc.MD在第二季度將其在Blueprint Medicines股票的頭寸增加了14.2%。Price T Rowe Associates Inc.MD現在持有這家生物技術公司5,631,687股股票,價值284,457,000美元,此前該公司在上個季度增持了698,562股票。最後,安大略省養老金計劃信託基金的Healthcare在第二季度購買了Blueprint Medicines的新股份,價值約34,599,000美元。
Blueprint Medicines Company Profile
藍圖醫藥公司簡介
(Get Rating)
(獲取評級)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
BluePrint Medicines Corporation是一家精準治療公司,在美國和國際上開發針對基因定義的癌症和血液疾病的藥物。該公司正在開發用於治療全身性肥大細胞增多症(SM)和胃腸道間質瘤的AYVAKIT;用於治療非進展性肥大細胞增多症和其他肥大細胞疾病的口服可用、有效的試劑盒抑制劑BLU-263;以及用於治療肝細胞癌的口服可用且有效的抑制劑Fisogatinib。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Blueprint Medicines (BPMC)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免費獲取StockNews.com關於藍圖藥物的研究報告(BPMC)
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別,但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
接受藍圖藥物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Blueprint Medicines和相關公司的最新新聞和分析師評級的每日摘要。